If you are wondering whether Madrigal Pharmaceuticals at around US$499 per share is still good value after a strong multiyear run, you are not alone. The stock has a 7 day return of 0.5% decline, a 30 ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its approved liver disease med Rezdiffra. Madrigal’s thyroid hormone ...

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...